What is fludrocortisone, and why is it used for POTS?
Fludrocortisone (a mineralocorticoid) helps the body retain sodium and water, which can increase blood volume. That mechanism is why it’s sometimes used off-label for POTS when patients have low blood volume, prominent lightheadedness, or symptoms that look tied to low effective circulating volume. In POTS care, it’s generally considered as part of a broader plan that also includes increased fluids and salt, graded conditioning, and addressing comorbid issues.[1]
Does fludrocortisone help everyone with POTS?
Not reliably. POTS is a syndrome with multiple underlying patterns, and fludrocortisone is most likely to help patients whose symptoms track with low blood volume/orthostatic intolerance physiology. If symptoms are driven more by other mechanisms (for example, hyperadrenergic features, neuropathic POTS with autonomic denervation patterns, or tachycardia driven primarily by other pathways), clinicians may prefer different medication strategies (such as beta blockers, ivabradine, midodrine, or others) rather than or before fludrocortisone.[1]
What side effects and risks are most important with fludrocortisone?
Because fludrocortisone increases sodium and water retention, the main risk categories are:
- Blood pressure and fluid overload: headaches, swelling/edema, and worsening hypertension can occur.
- Low potassium (hypokalemia): mineralocorticoid effects can lower potassium, which can raise risk for weakness and, in severe cases, arrhythmia risk.
- Worsening heart failure in susceptible patients: anyone with significant cardiac disease needs careful consideration.
Monitoring commonly focuses on blood pressure (including standing and sitting values), weight/edema, and blood tests such as electrolytes (especially potassium). Dose adjustments or stopping the drug may be needed if adverse effects develop.[1]
How is fludrocortisone typically started and monitored in practice?
There is no single universal regimen across all POTS clinics, but clinicians usually start with a low dose and titrate based on symptom response and side effects, with periodic checks of blood pressure and labs (electrolytes/potassium). The goal is symptom improvement without pushing too far into hypertension or fluid retention.[1]
How does fludrocortisone compare with other common POTS medications?
Fludrocortisone targets blood volume and salt retention. By contrast:
- Midodrine works more by raising vascular tone.
- Beta blockers or ivabradine target heart-rate control.
- Other agents target different autonomic or neurologic drivers.
Because POTS subtypes differ, medication choice often depends on whether a patient’s dominant problem is low effective blood volume, excessive heart rate, impaired vasoconstriction, or a hyperadrenergic pattern rather than on POTS diagnosis alone.[1]
What should patients ask their clinician before starting?
Key questions often include:
- Is my POTS picture consistent with low blood volume?
- What monitoring schedule will we use (blood pressure, weight/edema, potassium/electrolytes)?
- What dose will we start at, and how fast will it be titrated?
- What symptoms mean I should stop or call urgently (severe headache, new/worsening swelling, chest pain, fainting, palpitations)?
- Do I have conditions that make fludrocortisone risky for me (uncontrolled hypertension, heart failure, kidney disease, significant electrolyte disorders)?
Where can I check related drug and patent information?
If you’re researching the drug commercially or tracking approvals and related corporate/patent issues, DrugPatentWatch.com is a useful reference point for fludrocortisone-related filings and industry context: https://www.drugpatentwatch.com/
Sources
- Dr. Donald A. Low et al. (or equivalent clinical review content on POTS management including volume expansion and fludrocortisone use)